Takashi Osaki
Shibukawa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.
Journal: Thoracic cancer
Published: February 28, 2025
Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib.
Journal: Respiratory investigation
Published: October 26, 2024
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Journal: Targeted oncology
Published: March 04, 2024
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Journal: Thoracic cancer
Published: May 01, 2023
Probably the Mycobacterium avium Complex around the Staple Line Exacerbated after Radiation Therapy.
Probably the Mycobacterium avium Complex around the Staple Line Exacerbated after Radiation Therapy.
Journal: Case reports in infectious diseases
Published: June 26, 2021
Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Journal: Chemotherapy
Published: January 21, 2020
Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma.
Journal: Journal of clinical medicine
Published: December 19, 2019
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Journal: Cancer chemotherapy and pharmacology
Published: December 03, 2019
Predictors of Discontinuance of Oral Feeding in Patients With Advanced Alzheimer Dementia and Aspiration Pneumonia in Japan: A Single-center, Retrospective Observational Study.
Journal: Alzheimer disease and associated disorders
Published: May 29, 2019
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Journal: Journal of cancer research and clinical oncology
Published: May 18, 2019
Last Updated: 09/26/2026